Gladstone Emilie, Smolina Kate, Morgan Steven G, Fernandes Kimberly A, Martins Diana, Gomes Tara
School of Population and Public Health (Gladstone, Smolina, Morgan), University of British Columbia, Vancouver, BC; Institute for Clinical Evaluative Sciences (Fernandes, Martins, Gomes); Li Ka Shing Knowledge Institute (Gomes), St. Michael's Hospital, Toronto, Ont.
CMAJ. 2016 Mar 1;188(4):E67-E72. doi: 10.1503/cmaj.150349. Epub 2015 Nov 30.
Comprehensive systems for surveilling prescription opioid-related harms provide clear evidence that deaths from prescription opioids have increased dramatically in the United States. However, these harms are not systematically monitored in Canada. In light of a growing public health crisis, accessible, nationwide data sources to examine prescription opioid-related harms in Canada are needed. We sought to examine the performance of 5 algorithms to identify prescription opioid-related deaths from vital statistics data against data abstracted from the Office of the Chief Coroner of Ontario as a gold standard.
We identified all prescription opioid-related deaths from Ontario coroners' data that occurred between Jan. 31, 2003, and Dec. 31, 2010. We then used 5 different algorithms to identify prescription opioid-related deaths from vital statistics death data in 2010. We selected the algorithm with the highest sensitivity and a positive predictive value of more than 80% as the optimal algorithm for identifying prescription opioid-related deaths.
Four of the 5 algorithms had positive predictive values of more than 80%. The algorithm with the highest sensitivity (75%) in 2010 improved slightly in its predictive performance from 2003 to 2010.
In the absence of specific systems for monitoring prescription opioid-related deaths in Canada, readily available national vital statistics data can be used to study prescription opioid-related mortality with considerable accuracy. Despite some limitations, these data may facilitate the implementation of national surveillance and monitoring strategies.
用于监测处方阿片类药物相关危害的综合系统提供了明确证据,表明美国处方阿片类药物导致的死亡人数急剧增加。然而,加拿大并未对这些危害进行系统监测。鉴于日益严重的公共卫生危机,需要有可获取的全国性数据源来研究加拿大处方阿片类药物相关危害。我们试图检验5种算法从生命统计数据中识别处方阿片类药物相关死亡的性能,并将其与从安大略省首席验尸官办公室提取的数据(作为金标准)进行对比。
我们从安大略省验尸官数据中识别出2003年1月31日至2010年12月3日期间所有与处方阿片类药物相关的死亡案例。然后我们使用5种不同算法从2010年的生命统计死亡数据中识别与处方阿片类药物相关的死亡案例。我们选择灵敏度最高且阳性预测值超过80%的算法作为识别处方阿片类药物相关死亡的最佳算法。
5种算法中有4种的阳性预测值超过80%。2010年灵敏度最高(75%)的算法从2003年到2010年其预测性能略有提高。
在加拿大缺乏监测处方阿片类药物相关死亡的特定系统的情况下,现有的全国生命统计数据可用于较为准确地研究处方阿片类药物相关死亡率。尽管存在一些局限性,但这些数据可能有助于实施国家监测策略。